Stocks Screener

Specify a stock or a cryptocurrency in the search bar to get a summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Apellis Pharmaceuticals Inc

APLS
Current price
28.83 USD -1.1 USD (-3.68%)
Last closed 28.08 USD
ISIN US03753U1060
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 3 477 636 864 USD
Yield for 12 month -39.05 %
1Y
3Y
5Y
10Y
15Y
APLS
21.11.2021 - 28.11.2021

Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA). The company also develops APL-3007, a small interfering RNA, or siRNA, which is in a Phase 1 clinical trial, as well as an oral complement inhibitor that is in preclinical development. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) for development and commercialization of pegcetacoplan; and a collaboration with Beam Therapeutics Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. The company was incorporated in 2009 and is based in Waltham, Massachusetts. Address: 100 Fifth Avenue, Waltham, MA, United States, 02451

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
AAPL AAPL Apple
MSFT MSFT Microsoft

Analytics

WallStreet Target Price

62.89 USD

P/E ratio

Dividend Yield

Current Year

+396 591 000 USD

Last Year

+75 422 000 USD

Current Quarter

+199 685 000 USD

Last Quarter

+172 325 000 USD

Current Year

+336 377 000 USD

Last Year

+69 786 000 USD

Current Quarter

+176 136 000 USD

Last Quarter

+151 672 000 USD

Key Figures APLS

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
EBITDA -311 300 000 USD
Operating Margin TTM -14.75 %
PE Ratio
Return On Assets TTM -21.51 %
PEG Ratio
Return On Equity TTM -109.19 %
Wall Street Target Price 62.89 USD
Revenue TTM 628 785 984 USD
Book Value 2.17 USD
Revenue Per Share TTM
Dividend Share
Quarterly Revenue Growth YOY 110.3 %
Dividend Yield
Gross Profit TTM 69 786 000 USD
Earnings per share -2.77 USD
Diluted Eps TTM -2.77 USD
Most Recent Quarter II 2024
Quarterly Earnings Growth YOY
Profit Margin -52.94 %

Dividend Analytics APLS

Dividend growth over 5 years

Continuous growth

Payout Ratio 5 years average

Dividend History APLS

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
Ex Dividend Date
Forward Annual Dividend Yield
Last Split Factor
Payout Ratio
Last Split Date
Dividend Date

Stock Valuation APLS

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE
Enterprise Value Revenue 5.6004
Price Sales TTM 5.5307
Enterprise Value EBITDA -12.123
Price Book MRQ 12.8894

Financials APLS

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Technical indicators APLS

For 52 weeks

26.28 USD 73.8 USD
50 Day MA 32.06 USD
Shares Short Prior Month 15 260 698
200 Day MA 44.94 USD
Short Ratio 6.81
Shares Short 21 088 064
Short Percent 23.91 %